What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...
4A10, a monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα; CD127), has received fast track designation from the FDA for the treatment of patients with relapsed or refractory acute ...
Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
Ziftomenib is the first Menin inhibitor approved for relapsed or refractory mutant nucleophosmin 1 acute myeloid leukemia, showing promising efficacy in clinical trials. The phase 2 KOMET-001 trial ...
In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...
Targeted Therapies in Oncology | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback